RxDoctor Payments Data

Jeana Townsend, APRN

Family · Madisonville, KYNPI 1528471208

Payments from drug & device makers

$917in general payments, 2019–2025

Across 49 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$289
  • AstraZeneca$265
  • Axsome Therapeutics, Inc.$161
  • Lilly USA, LLC$101
  • Phathom Pharmaceuticals, Inc.$35
  • Amgen$28
  • plus $39 from 3 others

What the payments were for

  • Food & beverage$89497%
  • Education$233%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$917 in reported general payments places this provider in the 60th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$72,474
Medicare patients
283
Services billed
1,504

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$74,609
MounjaroTirzepatide55$56,484
EliquisApixaban41$45,177
JardianceEmpagliflozin40$30,623
TrulicityDulaglutide18$29,409
VraylarCariprazine Hcl16$22,116
JanuviaSitagliptin Phosphate29$21,205
XareltoRivaroxaban21$17,432
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,457
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$9,554
Breo ElliptaFluticasone/Vilanterol20$8,603
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr20$8,478
Albuterol Sulfate HfaAlbuterol Sulfate142$4,016
SynthroidLevothyroxine Sodium34$2,222
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$2,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$101$85,89373 claims
Novo NordiskOzempic$14$74,60971 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$13$28,53858 claims
AbbVieVraylar, Synthroid$289$24,33850 claims
AstraZenecaBreztri Aerosphere$265$9,55411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,374 family providers in Kentucky.

Other family in Madisonville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →